Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.

@article{Zuberbier2012PharmacologicalRF,
  title={Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.},
  author={Torsten Zuberbier},
  journal={Journal of the European Academy of Dermatology and Venereology : JEADV},
  year={2012},
  volume={26 1},
  pages={9-18}
}
Chronic urticaria (CU) is a long-lasting and distressing condition that impairs patient quality of life (QoL) by disrupting sleep and diminishing work/school productivity. Thus treatment should not only be safe and effective but also not add to this impairment or increase risks to health or safety. Non-sedating second-generation antihistamines, with their long duration of action, pharmacodynamic properties that allow once-daily dosing and lack of drug-drug interactions and sedative effects, are… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 65 references

Risk of first-generation H1-antihistamines: A GA 2LEN position paper

  • MK Church, M Maurer, FER Simons
  • Allergy
  • 2010

Similar Papers

Loading similar papers…